A Case Studies Compendium supplement to Clinical Endocrinology News. This supplement was sponsored by Daiichi Sankyo, Inc.
• Background
• Current Visit
• Laboratory Results
• Clinical Discussion
• Endocrinologist Consultation
• New Treatment Regimen With Add-On Therapy
• Conclusions
Case 2 Topics
• Background
• Current Visit: Exam Findings
• Current Treatment Regimen
• Health History
• Laboratory Results
• Clinical Discussion
• Cardiologist Visit
• Three Months After Visiting the Cardiologist
• Add-On Therapy With Welchol for Patients With T2DM and CHD
• Treatment Goals for Alice
• Conclusions
Faculty/Faculty Disclosures
Yehuda Handelsman, MD, FACP, FACE
Medical Director
Metabolic Institute of America
Chair and Program Director
7th World Congress on InsulinResistance
Chair, International Committeefor Insulin Resistance
18372 Clark Street, Suite 212
Tarzana, CA 91356
E-mail:yhandelsman@pacbell.net
Web Site:www.TheMetabolicCenter.com
Dr Handelsman is a consultant for Bristol-Myers Squibb
Company, Daiichi Sankyo, Inc., GlaxoSmithKline, Medtronic, Merck, Tethys,
and Xoma; he has received clinical research grant funding from Daiichi Sankyo, Inc., GlaxoSmithKline, Novo Nordisk, and Takeda; and he ison the speakers bureau for AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Inc., GlaxoSmithKline, Merck, and Novartis. He also serves on the advisory board for CLINICAL ENDOCRINOLOGY NEWS.
Peter H. Jones, MD, FACP
Co-Director, Lipid Metabolism
and Atherosclerosis Clinic
Medical Director, Weight
Management Center
The Methodist Hospital
Associate Professor of Medicine
Section of Atherosclerosis andLipid Research
Baylor College of Medicine
Houston, TX 77030
E-mail: jones@bcm.tmc.edu
Dr Jones has disclosed that he has received support in the form of consulting agreements from Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., and Merck.
Copyright © 2010 Elsevier Inc.